FOXP4 and hepatocellular carcinoma: Li et al reported for the first time that a novel lncRNA, Forkhead box P4 antisense RNA 1 (FOXP4-AS1), exhibited upregulated expression in patients with colorectal cancer at late tumor stages and was associated with poorer overall survival.[15] Subsequently, upregulation of the FOXP4-AS1 expression was identified in osteosarcoma,[16] prostate cancer,[17] hepatocellular carcinoma,[18] gastric cancer,[19] cervical cancer,[20] esophageal squamous cell carcinoma,[21] and pancreatic ductal adenocarcinoma,[22] and such upregulation was also indicative of poor prognosis.